Cargando…
Response to ‘The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors’
Autor principal: | Ogale, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225827/ https://www.ncbi.nlm.nih.gov/pubmed/30052727 http://dx.doi.org/10.1093/annonc/mdy260 |
Ejemplares similares
-
PD-L1 status and Immune checkpoint inhibitors in kidney cancer: ignorance, lack of knowledge or both
por: Tezval, Hossein, et al.
Publicado: (2021) -
Joint association of patients’ sex and PD‐L1 expression with overall survival benefits and tumor‐immune microenvironment in immune checkpoint inhibitors for cancers
por: Li, Anlin, et al.
Publicado: (2020) -
What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?
por: Bravaccini, Sara, et al.
Publicado: (2020) -
In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017) -
Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Thuru, Xavier, et al.
Publicado: (2022)